Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Clinical trial NCT07610720 · RECRUITING
Trial details
- NCT number
- NCT07610720
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2028-11-01
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.